Separately, Dr. Louise Pitt, Director, Center for Aerobiological Sciences, U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), presented data in a poster entitled, "Therapeutic Efficacy of Valortim((R)) an Anti-toxin Monoclonal Antibody, in the African Green Monkey Model of Inhalational Anthrax." Inhalational anthrax in certain primates such as African Green Monkeys (AGMs) is believed to follow a similar disease course as in humans.
In this randomized, blinded study, 48 AGMs were exposed by aerosol to Ames anthrax spores and blood samples were collected every 8 hours, beginning 24 hours post-exposure, to assess antigenemia (protective antigen 'PA' in circulation) and bacteremia. Samples were assayed for PA by a rapid electrochemiluminescence immunoassay (ECL), and bacteremia was confirmed by culture. The presence of PA in the blood of infected animals was the trigger for initiation of treatment with normal saline control, or Valortim((R)) at doses of 5, 10, 20 or 40 mg/kg.
In the study, AGMs were exposed by aerosol to Ames spores (approximately 200 LD(50)). Up to seventy percent (70%) of the Valortim((R))-treated animals survived. All AGMs were bacteremic at the time of treatment. These data suggest that Valortim((R) )may be a promising therapy for inhalational anthrax in symptomatic individuals and may have utility for use as rescue therapy.
The therapeutic efficacy study of Valortim((R)), given as a monotherapy in the AGM model, is being conducted by PharmAthene and its collaborators at USAMRIID, and has been funded in whole or in part with Federal funds from the Department of Defense through the United States Army Medical Research Institute of Infectious Di
|SOURCE PharmAthene, Inc.|
Copyright©2009 PR Newswire.
All rights reserved